TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did.
TB-500 and thymosin beta-4: what I expected, what I found, and the gap between them.
I am posting the gap rather than a theory about it. My theories about gaps like this one have not held up well.
The opening post answers the question as asked. The question underneath it is different.
TB-500 and thymosin beta-4 looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our favour.
Dose-response is unstudied in humans for essentially everything in this family, which means the confident numbers in circulation came from somewhere other than a trial.
That has been true for the cases I have seen and I have not seen many.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
Helpful, and short, which on this subject is harder than long.
Narrowing post #4, because the general version has more than one answer.
Two questions I would want answered before drawing anything from the TB-500 and thymosin beta-4 data above: how were the cases selected, and what happened to the ones that dropped out.
The practical version of TB-500 and thymosin beta-4 is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Answering the question post #6 raises rather than the one it answers.
Distinguishing three things in the TB-500 and thymosin beta-4 discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Source for the TB-500 and thymosin beta-4 figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
Post #10 is right about the mechanism and I think understates the practical bit.
TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.
Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
I had written a reply contradicting post #16 and deleted it. Here is what survived.
A request rather than an answer: could whoever has the primary source for TB-500 and thymosin beta-4 post it? I have seen the claim three times this month and each version had lost a qualifier.
Building on post #18 rather than restating it.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
The step people skip is the one I have spelled out.
On TB-500 and thymosin beta-4, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
The most useful thing anyone has posted about TB-500 and thymosin beta-4 in this category was a table of what had been measured and by whom. That is what I would want again.
The lyophilised cake is worth looking at before adding diluent. A collapsed or shrunken cake is not a purity finding but it does say something about how the vial was made and how it travelled.
I am not the right person to answer the follow-up to this.
Nothing in this subcategory is medical advice and several members here are describing experiments on themselves. Both of those things should be stated plainly rather than implied.
That is the version I use. It may not be the version that is correct.
The arithmetic in post #21 is right; the assumption feeding it is the part to check.
I would rather this thread reach "we do not know" about TB-500 and thymosin beta-4 than reach a confident answer that nobody can support when asked.
I think the TB-500 and thymosin beta-4 question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Helpful, and easy to find again, which is half of what a good reply is.
Adding the measurement that post #25 says would settle it.
Where the TB-500 and thymosin beta-4 reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Coming back to post #25, because the follow-up matters more than the original answer.
Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting.
I would not lead a decision with this, but I would not ignore it either.
Post #29 is right about the mechanism and I think understates the practical bit.
Speaking only to TB-500 and thymosin beta-4 as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.